Form 4: Adaptive Biotechnologies Director Katey Einterz Owen Reports Stock Option Grant and Common Stock Acquisition

Director Katey Einterz Owen reports acquisition of common stock and stock options in Adaptive Biotechnologies Corp.

Summary

• On March 4, 2025, Katey Einterz Owen, a director of Adaptive Biotechnologies Corp, acquired 15,394 shares of common stock.
• The acquisition was made at a price of $0.
• Following the transaction, Owen directly owns 72,629 shares of common stock.
• Owen also acquired a stock option to purchase 23,726 shares of common stock at an exercise price of $8.12.
• The stock options vest in equal monthly installments over one year from March 4, 2025, and expire on March 4, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The stock options vest monthly over one year, suggesting a continued relationship between the director and the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates